Form 4 for STLN Starling Oncology, Inc.
Accepted 2026-07-29 18:53:11 ET · period of report 2026-07-27 · accession 0001079973-26-000989 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-29 18:53 | 2026-07-27 | STLN | Pacala Mark L | Dir | A - Grant | $0.00 | +30.1K | 286.9K | +12% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-27 | A | A | 30,120 | $0.00 | 286,881 | D | — | — | (F1) Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date. |